Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria (Q34269834)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria |
scientific article |
Statements
1 reference
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority tria (English)
1 reference
Julio Rosenstock
1 reference
Alan J Garber
1 reference
Allen B King
1 reference
Stefano Del Prato
1 reference
Seamus Sreenan
1 reference
Mustafa K Balci
1 reference
Manuel Muñoz-Torres
1 reference
Lars A Endahl
1 reference
Ann Marie Ocampo Francisco
1 reference
Priscilla Hollander
1 reference
NN1250-3582 (BEGIN BB T2D) Trial Investigators
1 reference
Identifiers
1 reference